drugset / Trial / NCT00039858

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

NCT00039858

Phase 4 Completed 24 enrolled Encysive Pharmaceuticals GlaxoSmithKline · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.

Timeline

Start
2003-09
Primary completion
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Argatroban Small molecule